Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 17 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS: We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the apnea-hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline. Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure. RESULTS: At baseline, the mean AHI was 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2, and the mean body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) was 39.1 and 38.7, respectively. In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2) (P<0.001). In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9) (P<0.001). Significant improvements in the measurements for all prespecified key secondary end points were observed with tirzepatide as compared with placebo. The most frequently reported adverse events with tirzepatide were gastrointestinal in nature and mostly mild to moderate in severity. CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).
Overview
CoChat Summary
## TL;DR
In two 52-week phase 3 randomized controlled trials of adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide improved apnea-hypopnea index (AHI) and multiple secondary outcomes versus placebo. The paper concludes that tirzepatide reduced sleep-disordered breathing, body weight, hypoxic burden, hsCRP, systolic blood pressure, and improved sleep-related patient-reported outcomes.
## Key findings
- In trial 1, the mean change in AHI at week 52 was -25.3 events/hour with tirzepatide versus -5.3 events/hour with placebo; the estimated treatment difference was -20.0 events/hour (95% CI, -25.8 to -14.2; P<0.001).
- In trial 2, the mean change in AHI at week 52 was -29.3 events/hour with tirzepatide versus -5.5 events/hour with placebo; the estimated treatment difference was -23.8 events/hour (95% CI, -29.6 to -17.9; P<0.001).
- In the pooled analysis, participants receiving tirzepatide had significant reductions in PROMIS-SRI and PROMIS-SD T scores, and both trials showed significant reductions in body weight, systolic blood pressure, and hsCRP concentrations.
- The paper states that the most frequently reported adverse events with tirzepatide were gastrointestinal and generally mild-to-moderate; adverse events occurred in 79.8% vs 76.7% of participants in trial 1 and 83.2% vs 72.8% in trial 2 (tirzepatide vs placebo).
## Methods
- Two 52-week, phase 3, multicenter, parallel-group, double-blind, randomized, controlled trials were conducted at 60 sites across nine countries.
- Adults with moderate-to-severe obstructive sleep apnea (AHI ≥15 events/hour) and obesity (BMI ≥30; ≥27 in Japan) were enrolled; trial 1 included participants unable or unwilling to use PAP, and trial 2 included participants using PAP for at least 3 consecutive months and planning to continue.
- Participants were randomized 1:1 to weekly tirzepatide (10 mg or 15 mg maximum tolerated dose) or placebo; the primary endpoint was change in AHI from baseline, with key secondary endpoints including AHI percent change, body weight, hypoxic burden, hsCRP, patient-reported sleep outcomes, and systolic blood pressure. Analyses used ANCOVA and logistic regression, with multiplicity control via a graphical testing procedure.
## Limitations
- The paper states that the shorter duration of the trials does not support assessment of long-term cardiovascular outcomes.
- The trials excluded participants without obesity and did not assess people with overweight or normal BMI.
- The trials were not designed to test whether results differed by baseline symptoms, and trial 2 was not designed to assess PAP adherence effects; also, the minimum clinically important changes for PROMIS-SRI and PROMIS-SD were not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 6 Not checked · 57 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Excess adiposity is a major reversible etiologic risk factor for obstructive sleep apnea and its complications. 8,9”
What the sources say
- Supportedcites [8] 8. Hudgel DW, Patel SR, Ahasic AM, et al. The role of weight management in the treatment of adult obstructive sleep apnea: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2018;198(6):e70-e87. [PubMed: 30215551] source
The Introduction says weight gain is linked to the development and worsening of OSA and that obesity aggravates its metabolic and cardiovascular comorbidities. “Putting It All Together” reports that weight loss consistently improves OSA severity and may improve associated health outcomes, supporting reversibility. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [9] 9. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006;29:1031-5. [PubMed: 16944671] source
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This level of weight reduction has been difficult to accomplish with lifestyle intervention alone. 35”
What the sources say
- Partly supportedcites [35] 35. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014;348:g2646. [PubMed: 25134100] sourceExperimental — accuracy not yet measured
The Introduction says few people maintain weight loss over the long term, and the Behavioural/lifestyle v control section reports a modest mean difference of −1.56 kg at 12 months. This supports the general difficulty of sustaining weight loss with lifestyle intervention, but the claim does not specify what “this level” is, so the paper cannot verify that particular level. (LLM, conf=0.78)
- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The potential issue of PAP confounding of the PROMIS outcomes in trial 2 was minimized by a 7-day PAP washout period. 22”
What the sources say
- Partly supportedcites [22] 22. Schwarz EI, Stradling JR, Kohler M. Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model. J Thorac Dis 2018;10:Suppl 1:S24-S32. [PubMed: 29445525] sourceExperimental — accuracy not yet measured
The Physiological effects of CPAP withdrawal section reports that OSA recurred and subjective sleepiness increased one week after CPAP withdrawal, supporting the rationale for a washout. It does not assess PROMIS outcomes or establish that seven days minimized PAP confounding in trial 2; sleepiness continued to increase at two weeks. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile of tirzepatide was consistent with that observed in previous trials. 14,3739”
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16. [PubMed: 35658024] source
- Supportedcites [37] 37. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2023;402:613-26. [PubMed: 37385275] source
The Discussion explicitly states that tirzepatide’s safety profile was consistent with previous findings in the SURMOUNT-1 and SURPASS trials. The Safety section also describes the adverse events observed in this trial. (LLM, conf=0.95)
- Supportedcites [38] 38. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-18. [PubMed: 37840095] source
The Discussion explicitly states that tirzepatide’s safety profile in this trial was consistent with findings from previous tirzepatide trials. It also notes modestly higher rates of gastrointestinal adverse events and treatment discontinuation than in the tirzepatide 15 mg group in SURMOUNT-1; that qualification does not negate the overall comparison. (LLM, conf=0.95)
- Partly supportedcites [39] 39. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. [PubMed: 38078870] sourceExperimental — accuracy not yet measured
The Results (Adverse Events and Tolerability; page unavailable) describe tirzepatide’s safety findings, including gastrointestinal events and serious adverse events. The passages do not compare that safety profile with previous trials, so the claimed consistency with earlier findings is not established by our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were five cases of severe or serious depressive disorder or suicidal ideation or behavior events across both trials (two with tirzepatide and three with placebo).”
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
29 more claims
Create a free account to see all 77 claims and every source verdict.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, some studies were designed for other purposes17,18,30,41–44—for example, prevention of CVD or T2D.”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SURMOUNT-OSA trial reported that tirzepatide reduced the apnea-hypopnea index by 25% to 29% over 52 weeks in individuals with obesity and moderate to severe OSA, compared with a reduction of 5.3% to 5.5% in the placebo group, regardless of the use of positive airway pressure therapy (19).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Morrell, M. J., Nunez, C. M., Patel, S. R., Penzel, T., Pépin, J.-L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30198-5 · Cited by 4,326
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationAdult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine, Epstein, L. J., Kristo, D., Strollo, P. J., Friedman, N., Malhotra, A., Patil, S. P., Ramar, K., Rogers, R., Schwab, R. J., et al. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27497 · Cited by 3,360
Self-citationCPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
McEvoy, R. D., Antic, N. A., Heeley, E., Luo, Y., Ou, Q., Zhang, X., Mediano, O., Chen, R., Drager, L. F., Liu, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606599 · Cited by 2,101
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Adult obstructive sleep apnoea
Jordan, A. S., McSharry, D. G., & Malhotra, A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60734-5 · Cited by 1,735
Self-citationJavaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.069 · Cited by 1,434
Self-citationYeghiazarians, Y., Jneid, H., Tietjens, J. R., Redline, S., Brown, D. L., El-Sherif, N., Mehra, R., Bozkurt, B., Ndumele, C. E., Somers, V. K., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000988 · Cited by 1,431
Self-citationRamar, K., Dort, L. C., Katz, S. G., Lettieri, C. J., Harrod, C. G., Thomas, S. M., & Chervin, R. D. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4858 · Cited by 915
Azarbarzin, A., Sands, S. A., Stone, K. L., Taranto-Montemurro, L., Messineo, L., Terrill, P. I., Ancoli-Israel, S., Ensrud, K., Purcell, S., White, D. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy624 · Cited by 893
Self-citation
Cited by
Items 701–800 of 823
Le, D., Kilpatrick, M., Kraft, W. K., Grams, M. E., Jaar, B. G., & Shin, J.-I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106618
Tirzepatide as an Emerging Modality for Management of Obstructive Sleep Apnea
Gothi, D., Ish, P., & Malhotra, N. (2025) · Indian Journal of Sleep Medicine · doi:10.5005/jp-journals-10069-0151
Cree, M. G., Dunsmoor-Su, R. F., Khoudary, S. R. E., Hurtado, M. D., Kapoor, E., Neal-Perry, G. S., & Santoro, N. F. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100321
Hu, F. B., Beleslin, B., Blaha, M. J., Kris-Etherton, P. M., Seligman, H. K., & Williams, K. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.025 · Cited by 1
Has the time come for workplace screening for obstructive sleep apnoea (OSA)?
Kinoshita, R., Sathyapala, S. A., & Polkey, M. I. (2026) · Thorax · doi:10.1136/thorax-2025-223350
Modern methods for the diagnosis and management of obesity
Александровна, М. О., Валерьевна, Г. Е., Эдуардовна, Т. М., Martirosian, N. S., Кузина, И. А., Алексеевич, Т. А., Petunina, N. A., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-296
Sleep Apnea-Specific Hypoxic Burden and Postoperative Outcomes of Major Noncardiothoracic Surgery
Bailly, S., Sabil, A., Blanchard, M., Kerbrat, S., Goupil, F., Thomas, A., Thereaux, J., Fuchs, B., Couturaud, F., Jaber, S., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0006 · Cited by 1
Spiazzi, B. F., Zingano, C. P., Colpani, V., & Gerchman, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113431 · Cited by 3
Kooner, A. K., Man, L., Best, J., Litsky, N. M., Yee, B., & Jeffries, J. (2026) · Healthcare · doi:10.3390/healthcare14142069 · Cited by 1
Zheng, J., Zhu, Z., Bao, Y., Hu, Y., Dong, Z., Anshe, Z., Li, Q., Wang, Y., Zhu, M., & Chen, P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1869479
Zidek, W. (2025) · Diabetes aktuell · doi:10.1055/a-2624-1018
Chan, T. C., Brennan, J. J., Killeen, J. P., & Castillo, E. M. (2026) · Emergency Care and Medicine · doi:10.3390/ecm3030022
Richie, R. C., & Engman, M. L. (2026) · Springer eBooks · doi:10.1007/978-3-031-90919-1_27-1
Disparities in Medication Treatment of Type 2 Diabetes and Obesity
Whooten, R., Allen, L., & Stanford, F. C. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074840
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
Tirzepatide and Obesity: A Narrative Review
Singh, A., Ahmad, R., Chowdhury, K., Narwaria, M., & Haque, M. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_244_25 · Cited by 1
A Deadly Sleep: Obstructive Sleep Apnea and Hypoxemia
Dong, M., & Grewal, R. G. (2026) · Springer eBooks · doi:10.1007/978-3-032-18934-9_19
Johansson, E., Wilding, J. P. H., Upadhyay, N., van Hest, N., Kirk, M., Spaepen, E., Zimner‐Rapuch, S., Annemans, L., & Bays, H. E. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646078 · Cited by 1
Robinson, R., Sarkar, T. D., Moore, S., & Malhotra, A. (2026) · Current Sleep Medicine Reports · doi:10.1007/s40675-026-00373-z
Self-citationOh, J., & Choi, J. H. (2026) · Pharmaceuticals · doi:10.3390/ph19091361
Medications for the Management of Obesity
Giruzzi, N. R. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch29
New evidence linking lifestyle factors to blood pressure: Focus on 2024 findings
Matsumoto, C. (2026) · Hypertension Research · doi:10.1038/s41440-026-02549-0
Cagna, D. R., McKee, J. R., Metz, J. E., Marzola, R., Troeltzsch, M., Hoders, A. B., Schoenbaum, T. R., Blasi, Á., Irusa, K. F., Torresyap, V., et al. (2026) · Journal of Prosthetic Dentistry · doi:10.1016/j.prosdent.2026.08.003
The Role of Incretins in Obstructive Sleep Apnea “ GLP1RAs and GLP1RA / GIPRAs in OSA ”
Fuentes, A. L., Dhami, G., Pettus, J., Akuthota, P., & Malhotra, A. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70170 · Cited by 1
Self-citationVahedi, F., Yalamanchi, M., & Issa, D. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001134
Pulsatile liraglutide on a biased tirzepatide background: a hypothesis
Kopitović, I. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922908
Prieto, M. S., Romero-Dominguez, M., Orozco, R., Lilue, M., Lubián-López, D. M., González, S. P., Nieto, A., Coronado, P., Sánchez‐Borrego, R., Cano, A., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109101
Weight and sleep health in OSA: exploring their link
Beatty, C., Landry, S. A., Mann, D., Joosten, S. A., Day, K., Bonham, M. P., O’Driscoll, D. M., Young, A. C., Ghazi, L., Murgia, C., et al. (2026) · Frontiers in Sleep · doi:10.3389/frsle.2026.1828583
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Continuity of care in obesity clinical care
Lesmes, I. B., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501658 · Cited by 1
Corrado, R., Raffa, S. D., Bauer, E. M., Eisenberg, D., Weare-Regales, N., Antonovich, N., Loblack, A., Berdiel, E., Kelber, M. S., Klimovich, J., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00676
Haidar, L., & Delaney, J. A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001059 · Cited by 1
(2024) · Nursing · doi:10.1097/nsg.0000000000000073
Jaganathan, N., Goel, V., Liu, X., Song, W., Kwon, Y., Logan, J. G., & Healy, W. J. (2026) · Advances in Geriatric Medicine and Research · doi:10.20900/agmr20260020
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag043
CLINICAL CHARACTERISTICS OF USERS OF WEIGHT LOSS DRUGS: POPULATION-BASED CASE-CONTROL STUDYPreprint
Bakken, I. J., Ruiz, P. L., Furu, K., et al. (2026) · medRxiv · doi:10.64898/2026.02.04.26345477
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
The Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP ‐1 Agonists
Wani, S., Findakly, S., Phan, T. D., Lukies, M. W., Goh, G. S., Venn, G., Joseph, T., Koukounaras, J., & Clements, W. (2025) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.70045
Pharmacologic glycemic management of type 2 diabetes
Mourelatou, N. G., & Rebelos, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00284-3
Neurobiology of sleep apnea and cognitive impairment
Sharafkhaneh, A., & BaHammam, A. S. (2026) · Progress in brain research · doi:10.1016/bs.pbr.2026.07.008
Benmohammed, K., & Valensi, P. E. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.09.007
Dubaj, M., Piech, B., `Mzabi, S. K., Judzińska, A., Ignarska, J., Trojanowska, E., Sobczyńska, K., Terbosh, M., Osipowska, J., & Kwolek, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5603
Салухов, В. В., Galstyan, G. R., Неймарк, А. Е., Samoilov, V. S., Khalimov, Y. S., Karonova, T. L., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-155
Mathew, R., Box, N. R., Patri, S., REYES, S., Ploch, M., Lee, C., Pueringer, M., Estrada-Y-Martin, R. M., Zhang, S., & Cherian, S. V. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108999 · Cited by 1
Donovan, L. M. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-02124
Sleep apnea at the frontier— an integrated multidisciplinary functional framework
Beache, G. M., Hutchinson, B., Raman, B., Macey, P. M., Pham, N., Lozano, P. F. R., Redeker, N. S., & Somers, V. K. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102190 · Cited by 1
Sullivan, S. D. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-01469
Overview of Obstructive Sleep Apnea
Goh, L. C., Shariff, M. A. M., Din, A. R. B. M., Wong, L. K., Ismail, A. S. M., Laavanya, R., Sebastin, E. R., Ismail, N. A. E., Wong, C. K., Ismail, A. I., et al. (2026) · Springer eBooks · doi:10.1007/978-981-95-9749-9_1
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
Obesity and obstructive sleep apnea: from pathophysiology to current clinical approaches
Treptow, E. C., Carneiro, G., Andersen, M. L., Drager, L. F., & Genta, P. R. (2026) · Respiratory Research & Clinical Practice · doi:10.36416/1806-3756/e20250314
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
The Pharyngeal Resistance Index—A Promising Diagnostic Tool in OSA
Kern, N. L., Pugachev, A., Ebker, T., Elter, T., Voß, J. O., Bumann, A., Heiland, M., & Bigus, S. (2026) · Journal of Sleep Research · doi:10.1111/jsr.70341
Az elhízás és a testsúlycsökkentés szerepe obstruktív alvási apnoéban
Horváth, G., Berner, S. C., Bardóczi, A. B., Csoma, B., Müller, V., & Horváth, G. (2026) · Orvosi Hetilap · doi:10.1556/650.2026.33589
Tassoni, M. M., Chiusolo, S., Hoxhaj, D., Fabbrini, M., Gargani, L., Faraguna, U., Bonanni, E., & Caterina, R. D. (2026) · Heart · doi:10.1136/heartjnl-2025-325833
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Obesity and Obstructive Sleep Apnea
Estephan, L. E., & Huntley, C. T. (2026) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2026.05.007 · Cited by 1
Pillai, A. A., Godin, S., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001310 · Cited by 1
Flood, J., Cistulli, P. A., Tong, B., Mohammadieh, A. M., de Chazal, P., & Stewart, G. M. (2026) · Expert Review of Medical Devices · doi:10.1080/17434440.2026.2625362 · Cited by 2
Impact of Obesity Medications on Gastric Function
Torres, J. A., & Sullivan, S. A. (2026) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161261417564
Hypoglossal nerve peripheral stimulation (HNS) for sleep apnea
Ruan, Q. Z., Chopra, H., Khawer, A., Broachwala, M. Y., & AlFarra, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36528-7.00049-2
The Role of Pharmacotherapy for Excessive Daytime Sleepiness in OSA
Chapman, J. L., Tai, J. E., Harper, C., Grunstein, R. R., & Yee, B. J. (2026) · CHEST Pulmonary · doi:10.1016/j.chpulm.2026.100245
Self-citationTherapy management of patients with obstructive sleep apnea: Status and strategies for optimization
Arzt, M. E., Schoebel, C., Galetke, W., Woehrle, H., & Somnexus Group (2025) · Somnologie - Schlafforschung und Schlafmedizin · doi:10.1007/s11818-025-00514-6 · Cited by 1
Marino, A. B., Drake, E. S., Theroux, J. D., Osteen, R., Sarpong, R., Hughes, A., & Plummer, J. (2025) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000344
The impact of sleep on heart health: contemporary research and medical practice
Drakopanagiotakis, F., Gouveri, E., Steiropoulos, P., & Παπάνας, Ν. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001290 · Cited by 1
The role and mechanism of UPRmt in adipocytes
Liu, H.-N., Chen, J., Qiu, D.-Q., Jiang, M., Chen, H.-Q., Li, L., & Chen, S.-Q. (2026) · Adipocyte · doi:10.1080/21623945.2026.2651605
Cheng, T., Wang, Q., & Wei, W. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1846726
Non-positive Airway Pressure Therapies for Obstructive Sleep Apnoea and Central Sleep Apnoea
Mora, J., Sunwoo, B. Y., Ramsis, M., & Malhotra, A. (2026) · Cardiac failure review · doi:10.15420/cfr.2025.24 · Cited by 1
Self-citationKim, S., Barthel, A., Smurzynski, M., & MacEwan, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71033
Gironda, G., Sartori, G., Fantin, A., Castaldo, N., & Crisafulli, E. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107220
Peary, A., Vaidya, N., Jakicic, J., & Chao, A. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01426-y · Cited by 1
Delivery devices and container closure systems for co-formulated and co-administered biologics
Zhou, M., Duffy, K. H., Mitchener, C., Shi, G. H., & Collins, D. S. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag034
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Expert Consensus on the Management of Obesity in Older Adults (2026 Edition)
Pan, Q., & Guo, L. (2026) · Aging Medicine · doi:10.1002/agm2.70105
Microdosing Tirzepatide in Multi‐Dose Pens: Clinical Individualization, Safety, and Evidence Gaps
Lara, F. V.-O. D. (2026) · Obesity · doi:10.1002/oby.70282
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
Updates in the Management of Patients with Obstructive Sleep Apnea
Davies, A., Jaganathan, N., Cho, Y., Liu, X., Healy, S. J., Kwon, Y., & Healy, W. J. (2025) · Southern Medical Journal · doi:10.14423/smj.0000000000001838 · Cited by 1
Aneni, E. C., Karim, I., Rutter, J., Olaseni, O., Kreinin, I., Tsang, S. W., Wang, Z., Strohl, K. P., Yaggi, H. K., & Neeland, I. J. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108134
Wong, S., Kendzerska, T., & Mak, M. S. B. (2026) · Brain Sciences · doi:10.3390/brainsci16080799
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156026
Kasaie, P., Zhao, Y., Humes, E., Gerace, L., Reid, K. A., Lesko, C. R., Kurgansky, K. E., Koethe, J. R., Rebeiro, P. F., Bourgi, K., et al. (2025) · medRxiv · doi:10.1101/2025.11.05.25339607
Wolsing, S. K., Dogan, A. D. A., Juhl, C. B., Hess, S., Jensen, T. T., Bladbjerg, E., & Hilberg, O. (2026) · Clinical Obesity · doi:10.1111/cob.70079
Pharmacological treatment of obstructive sleep apnea syndrome
Tardov, M. V., Boldin, A. V., Афанасьевич, Ф. А., Kotidis, I. M., Бокова, И. А., Tardova, V. M., & Bokova, O. A. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612605248 · Cited by 1
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
Ciołkosz, K., & Polak-Szczybyło, E. (2026) · Nutrients · doi:10.3390/nu18193131
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Joshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
Horner, R. L. (2026) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2026.05.001
Vukoja, M. K., Bojović, M., Kopitović, I., Janjic, S. D., Novković, L., Čekerevac, I., Stanković, I., Božanić, B., Hromiš, S., Zvezdin, B., et al. (2026) · Medical Sciences · doi:10.3390/medsci14020253
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Beyond coexistence: attempting to unlock the diabetes–COMISA link
Sankari, A. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00135-2
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
SURMOUNT-OSA: Tirzepatide verbetert de symptomen van slaapapneu
Muskiet, M. H. A. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1568-5
Metadata
- Authors
- Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., & Bednarik, J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the University of California, San Diego, La Jolla (A.M.); Woolcock Institute of Medical Research, Macquarie University, Royal Prince Alfred Hospital, and the University of Sydney — all in Sydney (R.R.G.); the Center of Sleep Medicine, Charité University Hospital Berlin, Berlin (I.F.); the College of Nursing, University of Illinois Chicago, Chicago (T.E.W.); the School of Nursing (T.E.W.) and Perelman School of Medicine (R.J.S.), University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (S.R., A.A., S.A.S.); and Eli Lilly, Indianapolis (J.P.D., S.C., M.C.B., J.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-03
- Volume
- 391
- Issue
- 13
- Pages
- 1193-1205
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11598664
- OpenAlex
- W4399907994
- Cited by
- 871
- References
- 39
- Citations by year
- 2026: 410 · 2025: 379 · 2024: 80
- FWCI
- 245.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Keywords
- tirzepatide, obstructive sleep apnea, obesity, GLP-1 receptor agonists, GIP receptor agonist, apnea-hypopnea index, weight loss, positive airway pressure, hypoxic burden, sleep disorders, C-reactive protein, systolic blood pressure, cardiovascular risk, anti-obesity drugs, obesity-related sleep apnea, body mass index
- MeSH terms
- Sleep Quality, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Hypoxia, Blood Pressure, Body Weight, C-Reactive Protein, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Male, Middle Aged, Obesity, Severity of Illness Index, Treatment Outcome, Sleep Apnea, Obstructive, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.